Adult: Combination therapy w/ FU/FA: 85 mg/m2 every 2 wk, given via infusion over 2-6 hr for 12 cycles. Dose may be reduced to 65 mg/m2, according to tolerability.
Intravenous Adjuvant therapy in stage III colon cancer
Adult: Combination therapy w/ fluorouracil (FU)/folinic acid (FA): 85 mg/m2 every 2 wk, given via infusion over 2-6 hr for 12 cycles. Dose may be reduced to 75 mg/m2, according to tolerability.
Renal Impairment
CrCl (mL/min)
Dosage
<30
Contraindicated.
Reconstitution
Dilute the required dose w/ 250-500 mL of dextrose 5% in water, to provide a soln containing 0.2-0.7 mg/mL.
Incompatibility
Incompatible w/ Cl-containing solutions. Alkaline agents or soln (e.g. 5-FU, trometamol) negatively affect the stability. Needles and IV admin sets containing Al can cause degradation of platinum compd.
Contraindications
Hypersensitivity to oxaliplatin and other platinum agents. Myelosuppression, peripheral sensory neuropathy w/ functional impairment, congenital long QT prolongation. Severe renal impairment (CrCl <30 mL/min). Lactation. Concomitant use w/ live vaccines.
Special Precautions
Patient w/ history of or risk for QT prolongation, electrolyte disturbances. Pregnancy.
This drug may cause dizziness, nausea, vomiting, vision abnormalities and other neurological symptoms that affect gait and balance, if affected, do not drive or operate machinery.
May enhance adverse effect of live vaccines. Potentially Fatal: May diminish the therapeutic effect of vaccines. Increased risk of torsade de pointes w/ QT interval prolonging drugs.
Action
Description: Mechanism of Action: Oxaliplatin is a platinum-containing antineoplastic drug which forms several transient reactive complexes including monoaquo and diaquo diaminocyclohexane platinum. These complexes covalently bind to DNA base sequences to form inter and intra-strand cross-links thereby inhibiting replication, transcription and cell division leading to cell death. Pharmacokinetics: Distribution: Volume of distribution: 440 L. Plasma protein binding: >90%, mainly to albumin and γ globulin. Metabolism: Undergoes rapid and extensive nonenzymatic metabolism into inactive and active metabolites. Excretion: Mainly via urine (approx 54%); faeces (approx 2%). Terminal elimination half-life: 391 hr.
Chemical Structure
Storage
Store between 20-25°C. Do not freeze. Protect from light. Reconstituted soln: Store between 2-8°C for up to 24 hr.
This is a cytotoxic drug. Follow applicable procedures for receiving, handling, admin, and disposal. Any unused portions should be disposed of in accordance w/ local requirements.
L01XA03 - oxaliplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
References
Anon. Oxaliplatin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 31/08/2017.Buckingham R (ed). Oxaliplatin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/08/2017.Joint Formulary Committee. Oxaliplatin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/08/2017.McEvoy GK, Snow EK, Miller J et al (eds). Oxaliplatin. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 31/08/2017.Oxaliplatin Injection (Sun Pharmaceutical Industries, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 31/08/2017.